Clinical trial NCT04667572: Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution
Official title: Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Keratoconus
Pellucid Marginal Corneal Degeneration
Corneal Degeneration
Corneal Ectasia
Lead sponsor: Cornea Associates of Texas
Sponsor class: OTHER
First posted: 2020-12-14
Enrollment: 249
Sex: ALL
Minimum age (years): 8
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-linking in Eyes With Corneal Thinning Conditions

Detailed description: Patients with progressive keratoconus, pellucid marginal degeneration, or at risk for post-refractive corneal ectasia will be recruited and undergo epithelial-on corneal crosslinking with the Peschke PXL-330 system using pulsed, accelerated energy delivery. Patients will undergo monitoring for 1 year, with serial measurements of corneal topography, visual acuity, pachymetry, and visual function.

Eligibility criteria: Inclusion Criteria:

* 8 years of age or older
* Signed written informed consent
* Willingness and ability to comply with schedule for follow-up visits
* Contact Lens Wearers Only:
* Removal of contact lenses (if applicable) for the required period of time prior to the screening refraction: Soft, discontinue 3 days; Soft Extended Wear, discontinue 3 days; Soft Toric, discontinue 3 days; Rigid gas permeable, discontinue 2 Weeks (subjects who cannot function without wearing their contact lenses, may forgo discontinuation of contact lenses)

And one or more of the following:

* Presence of central or inferior steepening.
* Axial topography consistent with keratoconus, post-surgical ectasia, or pellucid marginal degeneration
* Presence of one or more findings associated with keratoconus or pellucid marginal degeneration, such as: Fleischer ring, Vogt's striae, Decentered corneal apex, Munson's sign, Rizzutti's sign, Apical Corneal scarring consistent with Bowman's breaks, Scissoring of the retinoscopic reflex, Crab-claw appearance on topography
* Steepest keratometry (Kmax) value ≥ 47.20 D
* I-S keratometry difference \> 1.5 D on the Pentacam/Orbscan map or topography map
* Posterior corneal elevation \>16 microns
* Thinnest corneal point \>300 microns

Exclusion Criteria:

* Eyes classified as either normal or atypical normal on the severity grading scheme.
* Corneal thickness \< 300 microns measured by ultrasonic pachymetry or pentacam.
* Previous ocular condition (other than refractive error) in the eye(s) to be treated that may predispose the eye for future complications, for example: History of or active corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, etc.) Clinically significant corneal scarring in the CXL treatment zone that is not related to keratoconus or, in the investigator's opinion, will interfere with the cross-linking procedure.
* Pregnancy (including plan to become pregnant) or lactation during the course of the study
* A known sensitivity to study medications
* Patients with nystagmus or any other condition that would prevent a steady gaze during the CXL treatment or other diagnostic tests.
* Patients with a current condition that, in the physician's opinion, would interfere with or prolong epithelial healing

Primary outcomes:
measure: K-Max
timeFrame: 12 Months
measure: K-Mean
timeFrame: 12 Months
Secondary outcomes:
measure: Uncorrected Visual Acuity
timeFrame: 12 Months
measure: Best Corrected Visual Acuity
timeFrame: 12 Months
measure: Central Pachymetry
timeFrame: 12 Months
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Cornea Associates of Texas
state: Texas
Study officials:
References: